ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

UCB Signs Pacts In Neuroscience

by Ann M. Thayer
March 4, 2013 | APPEARED IN VOLUME 91, ISSUE 9

Belgian drugmaker UCB has joined with two biotech firms in the neuroscience area. It will work for two years with California-based ConfometRx on drugs that modulate G protein-coupled receptor targets. As the largest family of signaling proteins, GPCRs are involved in most physiological processes. In another deal, UCB will pay a $20 million licensing fee and additional milestone fees for exclusive rights to Biotie’s tozadenant. The Finnish firm is developing the adenosine A2a receptor inhibitor as a Parkinson’s disease treatment. Under a 2010 R&D agreement with UCB, Biotie is still eligible for up to $340 million in milestone payments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment